Spyre Therapeutics, Inc. (SYRE)
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock?
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data
Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However, they only have Phase 2 assets, with SPY001 and SPY002 that recently showed encouraging Part A data. We still need to wait to see their placebo-controlled data, as well as their combo therapy data.
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
Spyre Therapeutics SYRE has given investors a classic biotech dilemma. The pipeline is advancing, the cash balance is large and the stock has already moved sharply higher.
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
Spyre Therapeutics SYRE has become a closely watched clinical-stage biotech stock as investors look ahead to a busy stretch of data readouts that could define the company's next phase. The company is focused on inflammatory bowel disease, or IBD, where it is developing long-acting antibodies and antibody combinations aimed at improving disease control, convenience and durability of response.
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.
Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset
Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally developed, long-acting antibody combinations. Positive Phase 2 data for SPY001 and SPY002 in ulcerative colitis validate SYRE's approach, with a third monotherapy readout and multiple rheumatology catalysts expected in 2026. SYRE's $1.18B cash position funds operations into 2H 2029, supporting robust clinical execution and mitigating near-term dilution risk.
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
